At 73, I take six medications daily—four prescription drugs and two over-the-counter pills—to manage my health. I track them meticulously, yet recent refills have introduced a recurring problem: my pills keep changing colors and shapes.
When I picked up my latest refill, I was surprised to find my blue pill had turned yellow. This wasn’t the first time. A few months ago, a white and blue capsule became white and purple. Before that, a pink tablet shifted to blue.
These changes aren’t just cosmetic. For someone who relies on multiple medications, consistency in appearance is critical for avoiding mix-ups. Swapping pills without clear communication can lead to confusion, missed doses, or even dangerous errors.
Pharmacies often cite manufacturing changes, supplier transitions, or generic substitutions as reasons for these alterations. While cost-saving measures may drive some decisions, patient safety should never take a backseat to convenience.
I’m not alone in this frustration. Many seniors face similar challenges when their trusted medications suddenly look different. Clear labeling and proactive communication from healthcare providers and pharmacies could prevent unnecessary stress and potential risks.
Related articles
STAT+: A political contest in the U.K. could shake up drug pricing
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
STAT+: Top U.S. officials pressured Germany to pay more for prescription drugs
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
Makary’s departure and Cassidy’s tenuous Senate seat
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
STAT+: The hunt for FDA’s next leader
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to...
STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their...